OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Mafalda Ramos, V. Foos, Anastasia Ustyugova, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 6, pp. 2153-2167
Open Access | Times Cited: 24
Mafalda Ramos, V. Foos, Anastasia Ustyugova, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 6, pp. 2153-2167
Open Access | Times Cited: 24
Showing 24 citing articles:
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge
Lei Si, Michael Willis, Christian Asseburg, et al.
Value in Health (2020) Vol. 23, Iss. 9, pp. 1163-1170
Open Access | Times Cited: 36
Lei Si, Michael Willis, Christian Asseburg, et al.
Value in Health (2020) Vol. 23, Iss. 9, pp. 1163-1170
Open Access | Times Cited: 36
Current trends in diabetes mellitus database research in Japan
Shun Kohsaka, Naru Morita, Suguru Okami, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S2, pp. 3-18
Open Access | Times Cited: 29
Shun Kohsaka, Naru Morita, Suguru Okami, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S2, pp. 3-18
Open Access | Times Cited: 29
A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes
Yilin Yoshida, Xi Cheng, Hui Shao, et al.
Current Diabetes Reports (2020) Vol. 20, Iss. 4
Closed Access | Times Cited: 30
Yilin Yoshida, Xi Cheng, Hui Shao, et al.
Current Diabetes Reports (2020) Vol. 20, Iss. 4
Closed Access | Times Cited: 30
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, et al.
Heart Failure Reviews (2020) Vol. 26, Iss. 3, pp. 603-622
Open Access | Times Cited: 29
Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, et al.
Heart Failure Reviews (2020) Vol. 26, Iss. 3, pp. 603-622
Open Access | Times Cited: 29
Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States
Odette S. Reifsnider, M. Feldman, Pratik Pimple, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 791-799
Open Access | Times Cited: 21
Odette S. Reifsnider, M. Feldman, Pratik Pimple, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 791-799
Open Access | Times Cited: 21
Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review
Mari Pesonen, Virpi Jylhä, Eila Kankaanpää
JBI Evidence Synthesis (2024) Vol. 22, Iss. 11, pp. 2194-2266
Open Access | Times Cited: 2
Mari Pesonen, Virpi Jylhä, Eila Kankaanpää
JBI Evidence Synthesis (2024) Vol. 22, Iss. 11, pp. 2194-2266
Open Access | Times Cited: 2
The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review
Zhen Ruan, Lisong Yang, Honghao Shi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2020) Vol. 21, Iss. 2, pp. 221-233
Closed Access | Times Cited: 13
Zhen Ruan, Lisong Yang, Honghao Shi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2020) Vol. 21, Iss. 2, pp. 221-233
Closed Access | Times Cited: 13
Cost–effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes
Mafalda Ramos, Anastasia Ustyugova, N. Hau, et al.
Journal of Comparative Effectiveness Research (2020) Vol. 9, Iss. 11, pp. 781-794
Open Access | Times Cited: 12
Mafalda Ramos, Anastasia Ustyugova, N. Hau, et al.
Journal of Comparative Effectiveness Research (2020) Vol. 9, Iss. 11, pp. 781-794
Open Access | Times Cited: 12
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Mafalda Ramos, Peng Men, Xu Wang, et al.
Cost Effectiveness and Resource Allocation (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 11
Mafalda Ramos, Peng Men, Xu Wang, et al.
Cost Effectiveness and Resource Allocation (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 11
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
Hui Shao, Abdul Jabbar Omar Alsaleh, Terry Dex, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 9, pp. 1659-1670
Open Access | Times Cited: 7
Hui Shao, Abdul Jabbar Omar Alsaleh, Terry Dex, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 9, pp. 1659-1670
Open Access | Times Cited: 7
Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds
Thomas Wilke, Nils Picker, Sabrina Müller, et al.
ClinicoEconomics and Outcomes Research (2022) Vol. Volume 14, pp. 319-332
Open Access | Times Cited: 6
Thomas Wilke, Nils Picker, Sabrina Müller, et al.
ClinicoEconomics and Outcomes Research (2022) Vol. Volume 14, pp. 319-332
Open Access | Times Cited: 6
Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model‐based simulation analysis using 10‐year real‐world data and targeted literature review
Zi‐Yang Peng, Chun‐Ting Yang, Huang‐Tz Ou, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1328-1337
Open Access | Times Cited: 5
Zi‐Yang Peng, Chun‐Ting Yang, Huang‐Tz Ou, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1328-1337
Open Access | Times Cited: 5
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
Rory J. McCrimmon, Karen Palmer, Abdul Jabbar Omar Alsaleh, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 6, pp. 1203-1214
Open Access | Times Cited: 5
Rory J. McCrimmon, Karen Palmer, Abdul Jabbar Omar Alsaleh, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 6, pp. 1203-1214
Open Access | Times Cited: 5
Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
George Gourzoulidis, C. Tzanetakos, Ioannis Ioannidis, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 4, pp. 371-380
Closed Access | Times Cited: 7
George Gourzoulidis, C. Tzanetakos, Ioannis Ioannidis, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 4, pp. 371-380
Closed Access | Times Cited: 7
Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China
Ahmed Salem, Peng Men, Mafalda Ramos, et al.
Journal of Comparative Effectiveness Research (2021) Vol. 10, Iss. 6, pp. 469-480
Open Access | Times Cited: 6
Ahmed Salem, Peng Men, Mafalda Ramos, et al.
Journal of Comparative Effectiveness Research (2021) Vol. 10, Iss. 6, pp. 469-480
Open Access | Times Cited: 6
Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
Zhen Ruan, Huimin Zou, Qing Lei, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2022) Vol. 22, Iss. 4, pp. 555-574
Closed Access | Times Cited: 4
Zhen Ruan, Huimin Zou, Qing Lei, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2022) Vol. 22, Iss. 4, pp. 555-574
Closed Access | Times Cited: 4
Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
Kristoffer Nilsson, Emelie Andersson, Sofie Persson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 748-757
Open Access | Times Cited: 3
Kristoffer Nilsson, Emelie Andersson, Sofie Persson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 748-757
Open Access | Times Cited: 3
Examining the impact of structural uncertainty across ten type 2 diabetes models: Results from the 2022 Mount Hood Challenge
James Altunkaya, Xinyu Li, Amanda Adler, et al.
Value in Health (2024) Vol. 27, Iss. 10, pp. 1338-1347
Open Access
James Altunkaya, Xinyu Li, Amanda Adler, et al.
Value in Health (2024) Vol. 27, Iss. 10, pp. 1338-1347
Open Access
CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
Gianni Ghetti, Lorenzo Pradelli, G Papageorgiou, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 97-109
Open Access | Times Cited: 1
Gianni Ghetti, Lorenzo Pradelli, G Papageorgiou, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 97-109
Open Access | Times Cited: 1
Role of Dipeptidyl Dipeptidase 4 Inhibitors in the Management of Diabetic Foot
Wenhui Yu, Tong Zhang, Heng Xu
The International Journal of Lower Extremity Wounds (2022) Vol. 23, Iss. 4, pp. 577-584
Closed Access | Times Cited: 2
Wenhui Yu, Tong Zhang, Heng Xu
The International Journal of Lower Extremity Wounds (2022) Vol. 23, Iss. 4, pp. 577-584
Closed Access | Times Cited: 2
Empagliflozin cost effective versus sitagliptin and saxagliptin
PharmacoEconomics & Outcomes News (2019) Vol. 839, Iss. 1, pp. 16-16
Closed Access
PharmacoEconomics & Outcomes News (2019) Vol. 839, Iss. 1, pp. 16-16
Closed Access
Vergleich der Gesundheitskosten von Typ-2 Diabetikern bei der Anwendung von Empagliflozin, DPP-4-Hemmern und GLP-1-Agonisten (Print)
et al. Wilke
Monitor Versorgungsforschung (2022) Vol. 15, Iss. 06/2022
Open Access
et al. Wilke
Monitor Versorgungsforschung (2022) Vol. 15, Iss. 06/2022
Open Access
